Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
8158 On Other Exchanges
8158 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

china regenerative medicine (8158) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHINA REGENERATIVE MEDICINE (8158)

Related News

No related news articles were found.

china regenerative medicine (8158) Related Businessweek News

No Related Businessweek News Found

china regenerative medicine (8158) Details

China Regenerative Medicine International Limited, an investment holding company, engages in the research and development of bio-medical and healthcare products, and medical techniques in the People's Republic of China. It operates through Tissue Engineering, Stem Cell, Cosmetic and Health Products, and Medical Products and Equipment segments. The company offers ActivSkin, a tissue-engineered skin product; Acellular Corneal Stroma for use in the treatment of ophthalmology; Calcined Bovine Bone, a protein-detracted natural bone regenerative product and a bone substitute material for inducing natural bone regeneration; and Acellular Small Intestinal Submucosa, which is applied to anal fistula disease. It is also involved in the research and development of Recombinant Human Acellular Dermal Matrix that is targeted and applied for second degree burns; Selective Acellular Skin for use as wound dressings; Acellular Amniotic Membrane, an anti-adhesion agent for muscle and tender rebuilding operations; and Absorbable Dental Membrane for jawbone defect restoration, which are in Stage II business development process. In addition, the company provides Cell Sheet-Autologous Chondrocyte Implantation, a medical technique for repairing knee and other relevant cartilage damages; and produces and sells cellular and stem cell therapy products. Further, it develops a series of cosmetic products and stem cell based anti-aging products; and offers contract research organization services of drug screening, drug efficacy, and toxicity assays in the pre-clinical drug development, as well as trades in medical products and equipment. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Wanchai, Hong Kong.

414 Employees
Last Reported Date: 07/29/15
Founded in 1995

china regenerative medicine (8158) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $1.2M
Executive Director
Total Annual Compensation: $1.4M
Compliance Officer and Executive Director
Total Annual Compensation: $1.4M
Compensation as of Fiscal Year 2015.

china regenerative medicine (8158) Key Developments

China Regenerative Medicine International Limited Appoints Tam Man Kin, Raymond as Chief Financial Officer

The board of directors of China Regenerative Medicine International Limited announced that Mr. Tam Man Kin, Raymond has been appointed as the Chief Financial Officer of the company with effect from October 30, 2015. Mr. Tam Man Kin, Raymond Tam has over 15 years of management experience in banking and finance industry. Prior to joining the Company, Mr. Tam served as the Project Director of Mineralogy Pty Ltd. and the Chief Financial Officer of Resourcehouse Ltd. Further, he worked at J.P. Morgan from 2006 to 2010 and held various management positions with The Hongkong and Shanghai Banking Corporation Limited from 1999 to 2006. He has also served as the Vice President (Asia Convention) of the World Leadership Alliance ­ World Economic Council, and as the Deputy Chairperson of Corporate Sector and Financial Services Committees of CPA Australia ­ Greater China in 2015.

China Regenerative Medicine International Limited Reports Unaudited Capital Expenditure Results for the First Quarter Ended July 31, 2015

China Regenerative Medicine International Limited reported unaudited capital expenditure results for the first quarter ended July 31, 2015. For the period, the company has posted purchase of property, plant and equipment was HKD 5,503,000. Acquisition of subsidiaries was HKD 33,132,000.

China Bio-Med Regeneration Technology Limited Reports Unaudited Consolidated Earnings Results for the First Quarter Ended July 31, 2015

China Bio-Med Regeneration Technology Limited reported unaudited consolidated earnings results for the first quarter ended July 31, 2015. For the quarter, the company reported revenue of HKD 1,588,000 against HKD 791,000 a year ago. Loss before income tax was HKD 48,221,000 against HKD 39,226,000 a year ago. Loss for the period attributable to owners of the company was HKD 44,603,000 or 0.271 cents basic loss per share against HKD 36,080,000 or 0.307 cents basic loss per share a year ago. The overall increase in revenue was primarily attributable to increase in revenue of its tissue engineering segment and medical products and equipment segment, as the Group introduced the CBB products into the market and newly acquired Tianjin Weikai which focuses on providing services and equipments for pre-clinical trial applications of stem cell as well as contract researches. The loss was attributable to the amortisation of intangible assets of approximately HKD 10.07 million compared to HKD 12.57 million in the first quarter of 2014, advertising expenses of approximately HKD 3.19 million, research and development costs of approximately HKD 8.27 million compared to HKD 4.56 million for the first quarter of 2014 and the increase in general administrative expenses, namely staff costs and office rental.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8158:HK $0.45 HKD +0.015

8158 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8158.
View Industry Companies

Industry Analysis


Industry Average

Valuation 8158 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,982.5x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,806.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA REGENERATIVE MEDICINE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at